$73.49
0.07% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US4576693075
Symbol
INSM
Sector
Industry

Insmed Incorporated Target price 2025 - Analyst rating & recommendation

Insmed Incorporated Classifications & Recommendation:

Buy
100%

Insmed Incorporated Price Target

Target Price $97.56
Price $73.44
Potential
Number of Estimates 16
16 Analysts have issued a price target Insmed Incorporated 2026 . The average Insmed Incorporated target price is $97.56. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 18 Analysts recommend Insmed Incorporated to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Insmed Incorporated stock has an average upside potential 2026 of . Most analysts recommend the Insmed Incorporated stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 363.71 470.50
19.17% 29.36%
EBITDA Margin -213.24% -195.99%
2.91% 8.09%
Net Margin -274.71% -200.36%
12.47% 27.06%

16 Analysts have issued a sales forecast Insmed Incorporated 2025 . The average Insmed Incorporated sales estimate is

$470m
Unlock
. This is
29.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$526m 44.69%
Unlock
, the lowest is
$441m 21.36%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $364m 19.17%
2025
$470m 29.36%
Unlock
2026
$1.0b 112.75%
Unlock
2027
$1.8b 83.49%
Unlock
2028
$2.7b 49.03%
Unlock
2029
$3.8b 38.38%
Unlock

5 Analysts have issued an Insmed Incorporated EBITDA forecast 2025. The average Insmed Incorporated EBITDA estimate is

$-922m
Unlock
. This is
18.90% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-807m 4.11%
Unlock
, the lowest is
$-1.1b 35.96%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-776m 15.69%
2025
$-922m 18.90%
Unlock
2026
$-645m 30.03%
Unlock
2027
$-27.7m 95.71%
Unlock

EBITDA Margin

2024 -213.24% 2.91%
2025
-195.99% 8.09%
Unlock
2026
-64.46% 67.11%
Unlock
2027
-1.51% 97.66%
Unlock

17 Insmed Incorporated Analysts have issued a net profit forecast 2025. The average Insmed Incorporated net profit estimate is

$-943m
Unlock
. This is
5.99% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-629m 37.23%
Unlock
, the lowest is
$-1.2b 16.28%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-999m 4.31%
2025
$-943m 5.65%
Unlock
2026
$-685m 27.28%
Unlock
2027
$-120m 82.48%
Unlock
2028
$486m 505.05%
Unlock
2029
$1.2b 137.02%
Unlock

Net Margin

2024 -274.71% 12.47%
2025
-200.36% 27.06%
Unlock
2026
-68.48% 65.82%
Unlock
2027
-6.54% 90.45%
Unlock
2028
17.77% 371.71%
Unlock
2029
30.43% 71.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.57 -5.26
4.31% 5.57%
P/E negative
EV/Sales 28.00

17 Analysts have issued a Insmed Incorporated forecast for earnings per share. The average Insmed Incorporated EPS is

$-5.26
Unlock
. This is
5.90% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.51 37.21%
Unlock
, the lowest is
$-6.50 16.28%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.57 4.31%
2025
$-5.26 5.57%
Unlock
2026
$-3.82 27.38%
Unlock
2027
$-0.67 82.46%
Unlock
2028
$2.71 504.48%
Unlock
2029
$6.43 137.27%
Unlock

P/E ratio

Current -13.15 159.37%
2025
-13.97 6.24%
Unlock
2026
-19.22 37.58%
Unlock
2027
-109.72 470.86%
Unlock
2028
27.09 124.69%
Unlock
2029
11.43 57.81%
Unlock

Based on analysts' sales estimates for 2025, the Insmed Incorporated stock is valued at an EV/Sales of

28.00
Unlock
and an P/S ratio of
28.25
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 36.22 139.71%
2025
28.00 22.70%
Unlock
2026
13.16 53.00%
Unlock
2027
7.17 45.50%
Unlock
2028
4.81 32.90%
Unlock
2029
3.48 27.74%
Unlock

P/S ratio

Current 36.55 176.89%
2025
28.25 22.70%
Unlock
2026
13.28 53.00%
Unlock
2027
7.24 45.50%
Unlock
2028
4.86 32.90%
Unlock
2029
3.51 27.74%
Unlock

Current Insmed Incorporated Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B of A Securities
Locked
Locked
Locked Mar 20 2025
RBC Capital
Locked
Locked
Locked Mar 19 2025
UBS
Locked
Locked
Locked Mar 06 2025
Guggenheim
Locked
Locked
Locked Feb 25 2025
RBC Capital
Locked
Locked
Locked Feb 25 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 21 2025
Analyst Rating Date
Locked
B of A Securities:
Locked
Locked
Mar 20 2025
Locked
RBC Capital:
Locked
Locked
Mar 19 2025
Locked
UBS:
Locked
Locked
Mar 06 2025
Locked
Guggenheim:
Locked
Locked
Feb 25 2025
Locked
RBC Capital:
Locked
Locked
Feb 25 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today